ANG Lifesciences India (BOM:540694) Total Receivables: ₹679.3 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:540694 ANG Lifesciences India Ltd BOM:540694
62 GF Score
Price ₹36.43
GF Value ₹30.51
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is ANG Lifesciences India Total Receivables?

ANG Lifesciences India BOM:540694 +4.26% 62 Total Receivables is ₹679.3 Mil as of Mar. 2026. GuruFocus rates BOM:540694 with a GF Score™ of 62/100 and a GF Value™ of ₹30.51 (Modestly Overvalued). The stock has 3 warning signs investors should review.

ANG Lifesciences India's Total Receivables for the quarter that ended in Mar. 2026 was ₹679.3 Mil.

ANG Lifesciences India Total Receivables Related Terms

ANG Lifesciences India Total Receivables Historical Data

* Premium members only.

The historical data trend for ANG Lifesciences India's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ANG Lifesciences India Total Receivables Chart

ANG Lifesciences India Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,031.37 846.67 740.85 675.29 679.31

ANG Lifesciences India Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 675.29 0.00 871.09 0.00 679.31
BOM:540694
62GF Score
ANG Lifesciences India Ltd BOM:540694
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ANG Lifesciences India Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of ₹679.3 Mil mean?
ANG Lifesciences India (BOM:540694) has a Total Receivables of ₹679.3 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on ANG Lifesciences India and its competitors.
Is ANG Lifesciences India's Total Receivables too high?
ANG Lifesciences India's current Total Receivables is ₹679.3 Mil. Overall, ANG Lifesciences India has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ANG Lifesciences India's Total Receivables compare to ZTS and UTHR?
ANG Lifesciences India's Total Receivables of ₹679.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on ANG Lifesciences India and its competitors. ANG Lifesciences India's current Total Receivables is ₹679.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANG Lifesciences India stock overvalued right now?
Based on GuruFocus' analysis, ANG Lifesciences India (BOM:540694) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹30.51, compared to a current price of ₹36.43 — trading 19.4% above its estimated fair value. The current Total Receivables is ₹679.3 Mil. ANG Lifesciences India's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For ANG Lifesciences India (BOM:540694), the current Total Receivables is ₹679.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ANG Lifesciences India (BOM:540694) Overvalued in 2026?

Based on GuruFocus' analysis, ANG Lifesciences India stock appears to be overvalued. The current stock price of ₹36.43 is trading 19.4% above its estimated GF Value™ of ₹30.51. GuruFocus considers ANG Lifesciences India to be Modestly Overvalued.

Key valuation signals for BOM:540694:

  • Total Receivables: ₹679.3 Mil
  • GF Value™: ₹30.51 vs. price of ₹36.43 (19.4% above fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the BOM:540694 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ANG Lifesciences India Business Description

Address Ranjit Avenue, B-Block, Darbara Complex, SCO 113, First Floor, District Shopping Complex, Amritsar, PB, IND, 143001
ANG Lifesciences India Ltd is engaged in the business of manufacturing and sales of finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials, liquid injection vials, ampoules, PFS, hard gelatin capsules, soft gelatin capsules, dry syrups, liquid syrups and suspension, lotions, etc. Its product portfolio comprises various therapeutic categories such as antibiotics, antivirals, antimalarial, antiulcer, carbapenem, corticosteroid, penicillin, beta-lactamase inhibitor, etc. Through its subsidiary, it is also involved in the business of printing and packing solutions. The group's reportable segments are Pharmaceuticals, which derive maximum revenue, and Packaging and printing. Geographically, it derives maximum revenue from India.
62GF Score

Get the complete analysis for BOM:540694

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹36.43
Price
₹30.51
GF Value